Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The cost to the NHS was £29.68 per 24 mcg 28-cap pack as of April 2017. The drug is available in the United States, Japan, Switzerland, India, Bangladesh, United Kingdom, and Canada.